Literature DB >> 14624462

SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.

Chengyu Wu1, Qin Guan, Yingjian Wang, Z Joe Zhao, G Wayne Zhou.   

Abstract

SHP-1 has been proposed to be a tumor suppressor gene for several cancers. The expression of SHP-1 protein is diminished or abolished in most leukemia and lymphoma cell lines and tissues, and in some non-hematopoietic cancer cell lines, such as estrogen receptor (ER) negative breast cancer cell lines and some colorectal cancer cell lines. However, we do not know whether the reduced SHP-1 expression is the cause of cancer diseases or the secondary effect of cancer developments. Here, we first demonstrate that SHP-1 has general tumor suppressing function in SHP-1 transfected cell lines. Transfected SHP-1 inhibits the growth of three lymphoma/leukemia cell lines (Ramos, H9, Jurkat) and one breast cancer cell line (HTB26). We also demonstrate a possible molecular mechanism for the tumor suppressing function of SHP-1: SHP-1 inhibits cell growth partly by negative regulation of activated JAK kinase. In addition, we find, for the first time, that SHP-1 down-regulates the level of TYK2 kinase in H9 cells and of JAK1 kinase in HTB26 cells, by accelerating their degradation. The SHP-1 accelerated degradation of JAK1 kinase in HTB26 cells was blocked with the treatment of MG132, a specific inhibitor for proteasome-mediated proteolysis. Our data suggest a new function of SHP-1 in the regulation of proteasome-mediated degradation pathway. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624462     DOI: 10.1002/jcb.10727

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  30 in total

1.  Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.

Authors:  Asma Beldi-Ferchiou; Nour Skouri; Cyrine Ben Ali; Ines Safra; Abderrahman Abdelkefi; Saloua Ladeb; Karima Mrad; Tarek Ben Othman; Mélika Ben Ahmed
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

2.  γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent.

Authors:  Peramaiyan Rajendran; Feng Li; Kanjoormana Aryan Manu; Muthu K Shanmugam; Ser Yue Loo; Alan Prem Kumar; Gautam Sethi
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Integrated analyses of genome-wide DNA occupancy and expression profiling identify key genes and pathways involved in cellular transformation by a Marek's disease virus oncoprotein, Meq.

Authors:  Sugalesini Subramaniam; John Johnston; Likit Preeyanon; C Titus Brown; Hsing-Jien Kung; Hans H Cheng
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

4.  SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  L-C Fan; C-W Shiau; W-T Tai; M-H Hung; P-Y Chu; F-S Hsieh; H Lin; H-C Yu; K-F Chen
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

5.  Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.

Authors:  Aruljothi Subramaniam; Muthu K Shanmugam; Tina H Ong; Feng Li; Ekambaram Perumal; Luxi Chen; Shireen Vali; Taher Abbasi; Shweta Kapoor; Kwang Seok Ahn; Alan Prem Kumar; Kam M Hui; Gautam Sethi
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

6.  Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor.

Authors:  Il-Rae Cho; Myungju Oh; Sang Seok Koh; Waraporn Malilas; Ratakorn Srisuttee; Byung Hak Jhun; Sandra Pellegrini; Serge Y Fuchs; Young-Hwa Chung
Journal:  Int J Mol Med       Date:  2012-01-03       Impact factor: 4.101

Review 7.  ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.

Authors:  D Perrotti; P Neviani
Journal:  Br J Cancer       Date:  2006-09-05       Impact factor: 7.640

8.  Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2.

Authors:  Yifen Wu; Rong Li; Junyi Zhang; Gang Wang; Bin Liu; Xiaofang Huang; Tao Zhang; Rongcheng Luo
Journal:  Onco Targets Ther       Date:  2015-09-14       Impact factor: 4.147

9.  Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.

Authors:  Hua Xiong; Zhao-Fei Chen; Qin-Chuan Liang; Wan Du; Hui-Min Chen; Wen-Yu Su; Guo-Qiang Chen; Ze-Guang Han; Jing-Yuan Fang
Journal:  J Cell Mol Med       Date:  2009-09       Impact factor: 5.310

10.  Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression.

Authors:  Ariel Ernesto Cariaga-Martinez; María Angelica Lorenzati; Mario Alejandro Riera; Marisa Angelica Cubilla; Andrés De La Rossa; Ernesto Martín Giorgio; María Mercedes Tiscornia; Esteban Mariano Gimenez; María Eugenia Rojas; Bárbara Julieta Chaneton; Dora Isabel Rodríguez; Pedro Darío Zapata
Journal:  Adv Urol       Date:  2009-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.